News & Updates
Filter by Specialty:
Mid-dose beta-blocker therapy tied to highest mortality reduction after AMI
Use of any beta-blocker dose results in a significant decrease in mortality following acute myocardial infarction (AMI) when compared with no treatment, reports a study. Doses >25 percent to 50 percent of the currently recommended target dose (RTD) are associated with highest mortality reduction within the first year after AMI, indicating that higher doses are not required.
Mid-dose beta-blocker therapy tied to highest mortality reduction after AMI
09 May 2023
Temporary ET break for pregnancy safe in the short term for breast cancer survivors
Temporary interruption of adjuvant endocrine therapy (ET) to allow for pregnancy has demonstrated short-term safety, with no increase in risk of breast cancer events, including distant recurrence, in hormone receptor–positive breast cancer survivors who have completed 18–30 months of adjuvant ET.
Temporary ET break for pregnancy safe in the short term for breast cancer survivors
09 May 2023
Low skeletal muscle mass with abdominal obesity ups diabetes risk
Low skeletal muscle mass accompanied by abdominal obesity is significantly associated with a higher risk of incident type 2 diabetes (T2D), irrespective of the glycometabolic parameters, reveals a study.
